<DOC>
	<DOCNO>NCT02787447</DOCNO>
	<brief_summary>The investigator postulate exploitation pro-immunogenic effect radiotherapy thymosin might result abscopal response among patient metastatic cancer . The research design evaluate efficacy toxicity patient treat hypofractionated radiotherapy combine thymosin alpha 1 . An exploratory biomarker analysis blood tumor sample also plan .</brief_summary>
	<brief_title>Radiotherapy Combined With Thymosin Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Thymalfasin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Newly diagnose metastatic lung adenocarcinoma harbor sensitize EGFR mutation ( L858R , exon 19 deletion ) , show stable disease 3 month TKI , evaluate twice PET/CT scan , brain MRI , abdomen ultrasound ( ≥3 measurable lesion , lesion n't receive local therapy ) Age 18 year old ECOG Performance Status 02 Adequate bone marrow , liver renal function , specify : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L ; Hemoglobin ≥ 8 g/dL ; Platelets ≥ 100 x 109/L ; Serum total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; AST ALT ≤ 2.5 x ULN ≤ 5 x ULN liver metastases present ; Serum creatinine ≤ 1.5 x upper limit normal creatinine clearance ≥ 60ml/min patient creatinine level institutional normal For woman childbearing potential , negative pregnancy test within 14 day prior start treatment Men woman childbearing age must willing use effective contraception treatment least 3 month thereafter Patients family sign informed consent Received chemotherapy TKI therapy Brain parenchyma leptomeningeal disease Concurrent malignancies nonmelanoma skin cancer require active ongoing treatment Any medical comorbidities would preclude radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hypofractionated Radiotherapy</keyword>
	<keyword>Thymosin Alpha 1</keyword>
	<keyword>Lung Adenocarcinoma</keyword>
	<keyword>Tyrosine Kinase Inhibitors</keyword>
</DOC>